Vantive

Vantive

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Vantive is a Boston-based, private healthcare company founded in 2019, emerging from a long-standing legacy in kidney care. It operates at the intersection of medical devices, digital health, and services, offering therapies for chronic and acute kidney disease alongside extracorporeal organ support. The company's strategy centers on integrating digital solutions and advanced services with its core therapeutic devices to improve patient care and expand access, particularly to home-based dialysis. Vantive is in a commercial stage, generating revenue from its established portfolio while actively developing and launching new innovations.

NephrologyAcute Organ SupportCritical Care

Technology Platform

Integrated ecosystem of medical devices for dialysis and extracorporeal organ support, combined with digital health solutions (remote monitoring, data analytics, telehealth tools) and advanced service platforms.

Opportunities

Significant growth is driven by the global push towards cost-effective home dialysis, creating demand for Vantive's integrated digital and service solutions.
Expansion into broader acute organ support (like ECCO₂R for ARDS) opens large new addressable markets beyond traditional kidney care.

Risk Factors

The company faces intense competition from large, established dialysis providers and must successfully execute a complex shift in patient care to home-based models.
Regulatory and reimbursement challenges for new digital tools and therapy indications pose additional hurdles to growth.

Competitive Landscape

Vantive competes directly with global dialysis giants Fresenius Medical Care and Baxter, as well as DaVita in clinic services. In acute organ support and digital health, it faces competition from other medtech players like Getinge and Asahi Kasei, as well as emerging digital therapy management platforms.